Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Allogeneic Stem Cell Transplantation (SCT) in Advanced Chronic Myeloid Leukemia (CML) Patients after Tyrosine Kinase Inhibitor (TKI) Therapy

Philipp D. le Coutre, Philipp Hemmati, Stefan Neuburger, Theis Terwey, Gero Massenkeil, Peter Daniel, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 4419.

https://doi.org/10.1182/blood.V112.11.4419.4419

Published: 2008

Journal Articles

Secondary Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Stefan Neuburger, MD, Philipp Hemmati, MD, Theis Terwey, MD, Gero Massenkeil, MD, Bernd Dörken, MD, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 4297.

https://doi.org/10.1182/blood.V112.11.4297.4297

Published: 2008

Journal Articles

Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).

Philipp Hemmati, Theis Terwey, Gero Massenkeil, MD, Philipp D. le Coutre, MD, Stefan Neuburger, Lam G Vuong, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 3276.

https://doi.org/10.1182/blood.V112.11.3276.3276

Published: 2008

Journal Articles

Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC).

Philipp Hemmati, Gero Massenkeil, MD, Theis Terwey, Stefan Neuburger, Philipp D. le Coutre, MD, Lam G Vuong, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 3278.

https://doi.org/10.1182/blood.V112.11.3278.3278

Published: 2008

Journal Articles

Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning (RIC) Is Effective for Long-Term Disease Control in High-Risk AML Patients in First Complete Remission.

Philipp G. Hemmati, MD, Gero Massenkeil, MD, Theis H. Terwey, MD, Stefan Neuburger, MD, Philipp le Coutre, MD, Lam Vuong, MD, Bernd Dorken, MD, Renate Arnold, MD

Blood (2007) 110 (11): 3020.

https://doi.org/10.1182/blood.V110.11.3020.3020

Published: 2007

Journal Articles

Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy.

Theis H. Terwey, MD, Gero Massenkeil, MD, Ingo Tamm, MD, Christoph Lutz, MD, Philipp Hemmati, MD, Stefan Neuburger, MD, Bernd Dorken, MD, Renate Arnold, MD

Blood (2006) 108 (11): 3004.

https://doi.org/10.1182/blood.V108.11.3004.3004

Published: 2006

Journal Articles

No Impact of Adverse Karyotype on Outcome after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Lymphoblastic Leukemia.

Ingo Tamm, MD, Gero Massenkeil, M.D., Mandy Wagner, Ph.D., Theis Terwey, M.D., Christoph Lutz, M.D., Stefan Neuburger, M.D., Christiane Bommert, M.D., Bernd Dörken, M.D., Renate Arnold, M.D.

Blood (2006) 108 (11): 3152.

https://doi.org/10.1182/blood.V108.11.3152.3152

Published: 2006

Journal Articles

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

Blood (2006) 108 (9): 2928–2936.

https://doi.org/10.1182/blood-2006-03-008706

Published: 2006

Journal Articles

Reduced Intensity Conditioning in Acute Leukemias: Long Term Follow-Up Confirms Sustained Complete Remissions.

Gero Massenkeil, MD, Stefan Neuburger, MD, Ingo Tamm, MD, Christoph Lutz, MD, Marion Nagy, PhD, Philipp Le Coutre, MD, Bernd Doerken, MD, Renate Arnold, MD

Blood (2004) 104 (11): 5147.

https://doi.org/10.1182/blood.V104.11.5147.5147

Published: 2004

Journal Articles

Donor Lymphocyte Infusions to Prevent Relapse in Acute Leukemias after Allogenic Stem Cell Transplantation.

Christoph Lutz, MD, Marion Nagy, PhD, Ingo Tamm, MD, Stefan Neuburger, MD, Bernd Doerken, MD, Renate Arnold, MD, Gero Massenkeil, MD

Blood (2004) 104 (11): 1642.

https://doi.org/10.1182/blood.V104.11.1642.1642

Published: 2004

NARROW

Allogeneic Stem Cell Transplantation (SCT) in Advanced Chronic Myeloid Leukemia (CML) Patients after Tyrosine Kinase Inhibitor (TKI) Therapy

Secondary Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).

Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC).

Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning (RIC) Is Effective for Long-Term Disease Control in High-Risk AML Patients in First Complete Remission.

Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy.

No Impact of Adverse Karyotype on Outcome after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Lymphoblastic Leukemia.

Reduced Intensity Conditioning in Acute Leukemias: Long Term Follow-Up Confirms Sustained Complete Remissions.

Donor Lymphocyte Infusions to Prevent Relapse in Acute Leukemias after Allogenic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only